Corneal injury from a variety of acute or chronic conditions can result in patients’ dissatisfaction with visual performance or surgical outcomes. Delayed or poor corneal healing from post-PRK surgery, infections, corneal ulcer, acute dry eye, and post-collagen cross-linking for keratoconus, and neurotropic keratitis are but a few acute conditions. Chronic conditions can include keratoconus, Fuch’s corneal dystrophy, contact lens intolerance, and chronic dry eye. Increasing the speed of recovery from acute or resolution of chronic corneal injury may translate into improved vision outcomes and increased patients’ satisfaction.
VT-1020 is related to a family of salivary and lacrimal peptides known as histatins that have potent wound healing, antimicrobial, and anti-inflammatory properties. In animal and in vitro studies, histatins have been shown to enhance corneal epithelial migration and spreading, increase the rate of wound closure from surgical procedures through rapid re-epithelization, and inhibit pro-inflammatory cytokines Il-6, IL-8,TNF-α, MMP-2, and MMP-9. These factors may mitigate corneal injury in both acute and chronic conditions.